| Mark L Miller, DO | |
|
329 Floyd Dr, Carrollton, KY 41008-8261 | |
| (502) 732-1082 | |
| Not Available |
| Full Name | Mark L Miller |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 329 Floyd Dr, Carrollton, Kentucky |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558474130 | NPI | - | NPPES |
| 000000526905 | Other | KY | ANTHEM |
| 64123722 | Medicaid | KY | |
| 50014320 | Other | KY | PASSPORT |
| 2831247000 | Other | KY | PASSPORT ADVANTAGE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 02963 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Norton Hospitals, Inc | Louisville, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centerwell Senior Primary Care Ky Psc | 8022492024 | 12 |
| Proactive Therapy, Inc | 0143245415 | 58 |
News Archive
Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug's bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.
Contrary to the prevailing belief that the HIV epidemic in the UK can be traced back to one source, a new study by Oxford and London scientists suggests that HIV spread via at least six independent virus introductions and subsequent transmission chains.
Malaria, a disease caused mainly by the parasites Plasmodium falciparum and Plasmodium vivax, (P. vivax) is associated with over 400,000 deaths each year.
› Verified 8 days ago
| Entity Name | Triad Health Systems, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831311299 PECOS PAC ID: 4082798699 Enrollment ID: O20100806000077 |
News Archive
Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug's bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.
Contrary to the prevailing belief that the HIV epidemic in the UK can be traced back to one source, a new study by Oxford and London scientists suggests that HIV spread via at least six independent virus introductions and subsequent transmission chains.
Malaria, a disease caused mainly by the parasites Plasmodium falciparum and Plasmodium vivax, (P. vivax) is associated with over 400,000 deaths each year.
› Verified 8 days ago
| Entity Name | Centerwell Senior Primary Care Ky Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376282038 PECOS PAC ID: 8022492024 Enrollment ID: O20220824003346 |
News Archive
Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug's bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.
Contrary to the prevailing belief that the HIV epidemic in the UK can be traced back to one source, a new study by Oxford and London scientists suggests that HIV spread via at least six independent virus introductions and subsequent transmission chains.
Malaria, a disease caused mainly by the parasites Plasmodium falciparum and Plasmodium vivax, (P. vivax) is associated with over 400,000 deaths each year.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark L Miller, DO 329 Floyd Dr, Carrollton, KY 41008-8261 Ph: (502) 732-1082 | Mark L Miller, DO 329 Floyd Dr, Carrollton, KY 41008-8261 Ph: (502) 732-1082 |
News Archive
Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug's bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.
Contrary to the prevailing belief that the HIV epidemic in the UK can be traced back to one source, a new study by Oxford and London scientists suggests that HIV spread via at least six independent virus introductions and subsequent transmission chains.
Malaria, a disease caused mainly by the parasites Plasmodium falciparum and Plasmodium vivax, (P. vivax) is associated with over 400,000 deaths each year.
› Verified 8 days ago
Daniel A Shields, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 309 11th St, Carrollton, KY 41008 Phone: 502-732-4321 | |
Cecil D Martin, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 309 11th St, Carrollton, KY 41008 Phone: 502-732-3272 Fax: 502-732-3284 | |
Karalee Bessinger, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 205 Marwill Dr, Carrollton, KY 41008 Phone: 502-732-6956 Fax: 502-732-8219 | |
Dr. Sarah Ruth Hollis, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 205 Marwill Dr, Carrollton, KY 41008 Phone: 502-732-6956 Fax: 502-732-8219 |